Efficacy of ß-lactam/ß-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum-ß-lactamase-producing enterobacteriaceae in hematological patients with neutropenia

Carlota Gudiol; Cristina Royo-Cebrecos; Edson Abdala; Murat Akova; Rocío Álvarez; Guillermo Maestro De La Calle; Angela Cano; Carlos Cervera; Wanessa T. Clemente; Pilar Martín-Dávila; Alison Freifeld; Lucía Gómez; Thomas Gottlieb; Mercè Gurguí; Fabián Herrera; Adriana Manzur; Georg Maschmeyer; Yolanda Meije; Miguel Montejo; Maddalena Peghin; Jesús Rodríguez-Baño; Isabel Ruiz-Camps; Teresa C. Sukiennik; Cristian Tebe; Jordi Carratalà

doi:10.1128/AAC.00164-17

Efficacy of ß-lactam/ß-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum-ß-lactamase-producing enterobacteriaceae in hematological patients with neutropenia

Carlota Gudiol, Cristina Royo-Cebrecos, Edson Abdala, Murat Akova, Rocío Álvarez, Guillermo Maestro De La Calle, Angela Cano, Carlos Cervera, Wanessa T. Clemente, Pilar Martín-Dávila, Alison Freifeld, Lucía Gómez, Thomas Gottlieb, Mercè Gurguí, Fabián Herrera, Adriana Manzur, Georg Maschmeyer, Yolanda Meije, Miguel Montejo, Maddalena PeghinJesús Rodríguez-Baño, Isabel Ruiz-Camps, Teresa C. Sukiennik, Cristian Tebe, Jordi Carratalà

Research output: Contribution to journal › Article › peer-review

44 Scopus citations

Abstract

ß-Lactam/ß-lactamase inhibitors (BLBLIs) were compared to carbapenems in two cohorts of hematological neutropenic patients with extended-spectrum- ß-lactamase (ESBL) bloodstream infection (BSI): the empirical therapy cohort (174 patients) and the definitive therapy cohort (251 patients). The 30-day case fatality rates and other secondary outcomes were similar in the two therapy groups of the two cohorts and also in the propensity-matched cohorts. BLBLIs might be carbapenemsparing alternatives for the treatment of BSI due to ESBLs in these patients.

Original language	English (US)
Article number	e00164-17
Journal	Antimicrobial Agents and Chemotherapy
Volume	61
Issue number	8
DOIs	https://doi.org/10.1128/AAC.00164-17
State	Published - Aug 2017

Keywords

Beta-lactam/beta-lactamase inhibitors
Bloodstream infection
ESBLs
Mortality
Neutropenia

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1128/AAC.00164-17

Fingerprint

Dive into the research topics of 'Efficacy of ß-lactam/ß-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum-ß-lactamase-producing enterobacteriaceae in hematological patients with neutropenia'. Together they form a unique fingerprint.

Cite this

Gudiol, C., Royo-Cebrecos, C., Abdala, E., Akova, M., Álvarez, R., De La Calle, G. M., Cano, A., Cervera, C., Clemente, W. T., Martín-Dávila, P., Freifeld, A., Gómez, L., Gottlieb, T., Gurguí, M., Herrera, F., Manzur, A., Maschmeyer, G., Meije, Y., Montejo, M., ... Carratalà, J. (2017). Efficacy of ß-lactam/ß-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum-ß-lactamase-producing enterobacteriaceae in hematological patients with neutropenia. Antimicrobial Agents and Chemotherapy, 61(8), Article e00164-17. https://doi.org/10.1128/AAC.00164-17

Efficacy of ß-lactam/ß-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum-ß-lactamase-producing enterobacteriaceae in hematological patients with neutropenia. / Gudiol, Carlota; Royo-Cebrecos, Cristina; Abdala, Edson et al.
In: Antimicrobial Agents and Chemotherapy, Vol. 61, No. 8, e00164-17, 08.2017.

Research output: Contribution to journal › Article › peer-review

Gudiol, C, Royo-Cebrecos, C, Abdala, E, Akova, M, Álvarez, R, De La Calle, GM, Cano, A, Cervera, C, Clemente, WT, Martín-Dávila, P, Freifeld, A, Gómez, L, Gottlieb, T, Gurguí, M, Herrera, F, Manzur, A, Maschmeyer, G, Meije, Y, Montejo, M, Peghin, M, Rodríguez-Baño, J, Ruiz-Camps, I, Sukiennik, TC, Tebe, C & Carratalà, J 2017, 'Efficacy of ß-lactam/ß-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum-ß-lactamase-producing enterobacteriaceae in hematological patients with neutropenia', Antimicrobial Agents and Chemotherapy, vol. 61, no. 8, e00164-17. https://doi.org/10.1128/AAC.00164-17

Gudiol C, Royo-Cebrecos C, Abdala E, Akova M, Álvarez R, De La Calle GM et al. Efficacy of ß-lactam/ß-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum-ß-lactamase-producing enterobacteriaceae in hematological patients with neutropenia. Antimicrobial Agents and Chemotherapy. 2017 Aug;61(8):e00164-17. doi: 10.1128/AAC.00164-17

@article{223b20f4648241c0b50da2fcf20f179c,

title = "Efficacy of {\ss}-lactam/{\ss}-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum-{\ss}-lactamase-producing enterobacteriaceae in hematological patients with neutropenia",

abstract = "{\ss}-Lactam/{\ss}-lactamase inhibitors (BLBLIs) were compared to carbapenems in two cohorts of hematological neutropenic patients with extended-spectrum- {\ss}-lactamase (ESBL) bloodstream infection (BSI): the empirical therapy cohort (174 patients) and the definitive therapy cohort (251 patients). The 30-day case fatality rates and other secondary outcomes were similar in the two therapy groups of the two cohorts and also in the propensity-matched cohorts. BLBLIs might be carbapenemsparing alternatives for the treatment of BSI due to ESBLs in these patients.",

keywords = "Beta-lactam/beta-lactamase inhibitors, Bloodstream infection, ESBLs, Mortality, Neutropenia",

author = "Carlota Gudiol and Cristina Royo-Cebrecos and Edson Abdala and Murat Akova and Roc{\'i}o {\'A}lvarez and {De La Calle}, {Guillermo Maestro} and Angela Cano and Carlos Cervera and Clemente, {Wanessa T.} and Pilar Mart{\'i}n-D{\'a}vila and Alison Freifeld and Luc{\'i}a G{\'o}mez and Thomas Gottlieb and Merc{\`e} Gurgu{\'i} and Fabi{\'a}n Herrera and Adriana Manzur and Georg Maschmeyer and Yolanda Meije and Miguel Montejo and Maddalena Peghin and Jes{\'u}s Rodr{\'i}guez-Ba{\~n}o and Isabel Ruiz-Camps and Sukiennik, {Teresa C.} and Cristian Tebe and Jordi Carratal{\`a}",

note = "Publisher Copyright: {\textcopyright} 2017 American Society for Microbiology.",

year = "2017",

month = aug,

doi = "10.1128/AAC.00164-17",

language = "English (US)",

volume = "61",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "8",

}

TY - JOUR

T1 - Efficacy of ß-lactam/ß-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum-ß-lactamase-producing enterobacteriaceae in hematological patients with neutropenia

AU - Gudiol, Carlota

AU - Royo-Cebrecos, Cristina

AU - Abdala, Edson

AU - Akova, Murat

AU - Álvarez, Rocío

AU - De La Calle, Guillermo Maestro

AU - Cano, Angela

AU - Cervera, Carlos

AU - Clemente, Wanessa T.

AU - Martín-Dávila, Pilar

AU - Freifeld, Alison

AU - Gómez, Lucía

AU - Gottlieb, Thomas

AU - Gurguí, Mercè

AU - Herrera, Fabián

AU - Manzur, Adriana

AU - Maschmeyer, Georg

AU - Meije, Yolanda

AU - Montejo, Miguel

AU - Peghin, Maddalena

AU - Rodríguez-Baño, Jesús

AU - Ruiz-Camps, Isabel

AU - Sukiennik, Teresa C.

AU - Tebe, Cristian

AU - Carratalà, Jordi

PY - 2017/8

Y1 - 2017/8

N2 - ß-Lactam/ß-lactamase inhibitors (BLBLIs) were compared to carbapenems in two cohorts of hematological neutropenic patients with extended-spectrum- ß-lactamase (ESBL) bloodstream infection (BSI): the empirical therapy cohort (174 patients) and the definitive therapy cohort (251 patients). The 30-day case fatality rates and other secondary outcomes were similar in the two therapy groups of the two cohorts and also in the propensity-matched cohorts. BLBLIs might be carbapenemsparing alternatives for the treatment of BSI due to ESBLs in these patients.

AB - ß-Lactam/ß-lactamase inhibitors (BLBLIs) were compared to carbapenems in two cohorts of hematological neutropenic patients with extended-spectrum- ß-lactamase (ESBL) bloodstream infection (BSI): the empirical therapy cohort (174 patients) and the definitive therapy cohort (251 patients). The 30-day case fatality rates and other secondary outcomes were similar in the two therapy groups of the two cohorts and also in the propensity-matched cohorts. BLBLIs might be carbapenemsparing alternatives for the treatment of BSI due to ESBLs in these patients.

KW - Beta-lactam/beta-lactamase inhibitors

KW - Bloodstream infection

KW - ESBLs

KW - Mortality

KW - Neutropenia

UR - http://www.scopus.com/inward/record.url?scp=85026384016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026384016&partnerID=8YFLogxK

U2 - 10.1128/AAC.00164-17

DO - 10.1128/AAC.00164-17

M3 - Article

C2 - 28584145

AN - SCOPUS:85026384016

SN - 0066-4804

VL - 61

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 8

M1 - e00164-17

ER -

Efficacy of ß-lactam/ß-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum-ß-lactamase-producing enterobacteriaceae in hematological patients with neutropenia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this